This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignee: Gilead Sciences, Inc.. Active years: 2022-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2024
Title: Matthew M Logan: Innovator in FXR Agonists
Introduction
Matthew M Logan is a notable inventor based in San Mateo, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of solid forms of FXR agonists. With a total of 2 patents to his name, Logan's work is paving the way for advancements in medical treatments.
Latest Patents
Logan's latest patents focus on novel solid forms of FXR agonists. The disclosures detail pharmaceutical compositions that contain one or more of these solid forms, as well as methods for using them in the treatment of conditions mediated by FXR. Additionally, the patents outline methods for obtaining such solid forms, showcasing Logan's innovative approach to pharmaceutical development.
Career Highlights
Matthew M Logan is currently employed at Gilead Sciences, Inc., where he continues to push the boundaries of pharmaceutical research. His work is instrumental in developing new treatments that can significantly impact patient care.
Collaborations
Logan collaborates with esteemed colleagues such as Derek M Dalton and Peter C Fung. These partnerships enhance the research and development process, fostering an environment of innovation and creativity.
Conclusion
Matthew M Logan is a prominent figure in the pharmaceutical industry, with a focus on FXR agonists. His contributions through patents and collaborations are vital for the advancement of medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile